Free tool
FAERS Monitor: Istalol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021516 or its brand name (Istalol, Timolol Maleate). Reports on generic versions are filed under their own applications.
Reports
7,905
Serious
3,740
47% of reports
Hospitalization
1,571
Death reported
443
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure982
- drug ineffective588
- eye pain453
- fatigue421
- eye irritation374
- dizziness299
- diarrhoea293
- vision blurred271
- nausea268
- off label use267
- headache257
- dyspnoea242
- intraocular pressure increased236
- ocular hyperaemia234
- death229
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 158 |
| 2005 | 194 |
| 2006 | 157 |
| 2007 | 144 |
| 2008 | 136 |
| 2009 | 141 |
| 2010 | 210 |
| 2011 | 222 |
| 2012 | 330 |
| 2013 | 122 |
| 2014 | 147 |
| 2015 | 259 |
| 2016 | 314 |
| 2017 | 351 |
| 2018 | 370 |
| 2019 | 408 |
| 2020 | 1,444 |
| 2021 | 417 |
| 2022 | 440 |
| 2023 | 514 |
| 2024 | 518 |
| 2025 | 558 |
| 2026 | 350 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,254 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 236 | 50.0 | 44.1 | 11,091 |
| treatment failureSignal | 982 | 31.9 | 30.1 | 29,133 |
| eye painSignal | 453 | 21.5 | 19.7 | 8,799 |
| eye irritationSignal | 374 | 17.4 | 15.8 | 5,741 |
| ocular hyperaemiaSignal | 234 | 13.2 | 11.6 | 2,614 |
| vision blurredSignal | 271 | 5.3 | 4.7 | 935 |
| dizziness | 299 | 1.6 | 1.4 | 67 |
| fatigue | 421 | 1.4 | 1.3 | 58 |
| diarrhoea | 293 | 1.2 | 1.1 | 11 |
| drug ineffective | 588 | 1.2 | 1.1 | 18 |
| dyspnoea | 242 | 1.1 | 1.0 | 4 |
| headache | 257 | 1.1 | 1.0 | 2 |
| nausea | 268 | 0.9 | 0.8 | 3 |
| off label use | 267 | 0.8 | 0.7 | 12 |
| death | 229 | 0.7 | 0.6 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.